Literature DB >> 12088418

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.

K Takeda1, M J Smyth, E Cretney, Y Hayakawa, N Yamaguchi, H Yagita, K Okumura.   

Abstract

Natural killer (NK) cells and interferon- (IFN) gamma have been implicated in immune surveillance against tumor development. Here we show tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is a type II membrane protein belonging to the TNF family and plays a critical role in the NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous growth of TRAIL-sensitive tumors. Administration of a neutralizing monoclonal antibody against TRAIL promoted outgrowth of subcutaneously inoculated TRAIL-sensitive tumors (L929, LB27.4, and Renca) but not TRAIL-resistant tumors (P815 and B16). Such a protective effect of TRAIL against TRAIL-sensitive tumors was abrogated in NK cell-depleted or IFN-gamma-deficient mice. These results suggested a substantial role of TRAIL as the effector molecule that eliminates subcutaneously developing TRAIL-sensitive tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12088418     DOI: 10.1006/cimm.2001.1896

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  54 in total

1.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

Review 2.  Hidden talents of natural killers: NK cells in innate and adaptive immunity.

Authors:  Megan A Cooper; Marco Colonna; Wayne M Yokoyama
Journal:  EMBO Rep       Date:  2009-09-04       Impact factor: 8.807

3.  Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.

Authors:  Jerome T Higgs; John S Jarboe; Joo Hyoung Lee; Diptiman Chanda; Carnellia M Lee; Champion Deivanayagam; Selvarangan Ponnazhagan
Journal:  Mol Cancer Res       Date:  2015-01-30       Impact factor: 5.852

4.  Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth.

Authors:  Atsushi Kawabata; Abdulgader Baoum; Naomi Ohta; Stephanie Jacquez; Gwi-Moon Seo; Cory Berkland; Masaaki Tamura
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

5.  8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.

Authors:  A Gmidène; A Saad; H Avet-Loiseau
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

6.  Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.

Authors:  Nicole Clarke; Ana M Jimenez-Lara; Emilie Voltz; Hinrich Gronemeyer
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

Review 7.  Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans?

Authors:  Anne Grosse-Wilde; Christopher J Kemp
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

8.  Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.

Authors:  Marie-Thérèse Melki; Héla Saïdi; Alexandre Dufour; Jean-Christophe Olivo-Marin; Marie-Lise Gougeon
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

9.  Role of cancer microenvironment in metastasis: focus on colon cancer.

Authors:  Stéphanie Gout; Jacques Huot
Journal:  Cancer Microenviron       Date:  2008-03-14

10.  Immune and hemorheological changes in chronic fatigue syndrome.

Authors:  Ekua W Brenu; Donald R Staines; Oguz K Baskurt; Kevin J Ashton; Sandra B Ramos; Rhys M Christy; Sonya M Marshall-Gradisnik
Journal:  J Transl Med       Date:  2010-01-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.